Wai Yuen Tong Medicine Holdings Limited

SEHK:897 Stock Report

Market Cap: HK$229.5m

Wai Yuen Tong Medicine Holdings Valuation

Is 897 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 897 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 897 (HK$0.2) is trading below our estimate of fair value (HK$3.17)

Significantly Below Fair Value: 897 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 897?

Other financial metrics that can be useful for relative valuation.

897 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA6.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 897's PS Ratio compare to its peers?

The above table shows the PS ratio for 897 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
1643 Modern Chinese Medicine Group
0.8xn/aHK$219.0m
1312 Kontafarma China Holdings
0.3xn/aHK$223.5m
8329 Shenzhen Neptunus Interlong Bio-technique
0.2xn/aHK$226.5m
1498 PuraPharm
0.7xn/aHK$292.3m
897 Wai Yuen Tong Medicine Holdings
0.3xn/aHK$229.5m

Price-To-Sales vs Peers: 897 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.5x).


Price to Earnings Ratio vs Industry

How does 897's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a7.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a7.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 897 is good value based on its Price-To-Sales Ratio (0.3x) compared to the Hong Kong Pharmaceuticals industry average (1.5x).


Price to Sales Ratio vs Fair Ratio

What is 897's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

897 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 897's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies